Skip to main content
British Journal of Pharmacology logoLink to British Journal of Pharmacology
. 2020 Jan 16;176(24):4788. doi: 10.1111/bph.14941

CORRECTION

PMCID: PMC6965690  PMID: 31950491

The authors of Mao et al. (2019) have supplied the following correction to their article.

During creation and editing of the images for this article, Figures 1b, 2e, and 3b were confused. In Figure 1b, the photo of transwell assay of Dio 1.7 μM in SMC7721 cells came from that of HepG2 cells; the HE staining result of Dio 60 mg·kg−1 came from the control group in Figure 2e; the ki67 staining of Dio 20 mg·kg−1 and 5‐Fu 20 mg−kg−1 group were also confused with photos from the control group and Dio 40 mg·kg−1 groups in Figure 3b; the transwell assay results of TIGAR siRNA and TIGAR siRNA + dioscin group in Figure 6a were confused with photos from the other group.

The corrected figures are shown here.

Figure 1b.

Figure 1b

Figure 2e.

Figure 2e

Figure 3b.

Figure 3b

Figure 6a.

Figure 6a

CORRECTION. Br J Pharmacol. 2019;176:4788 10.1111/bph.14941

REFERENCE

  1. Mao, Z. , Han, X. , Chen, D. , Xu, Y. , Xu, L. , Yin, L. , … Peng, J. (2019). Potent effects of dioscin against hepatocellular carcinoma through regulating TP53‐induced glycolysis and apoptosis regulator (TIGAR)‐mediated apoptosis, autophagy, and DNA damage. British Journal Pharmacology, 176(7), 919–937. 10.1111/bph.14594 [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from British Journal of Pharmacology are provided here courtesy of The British Pharmacological Society

RESOURCES